Bionano Genomics (BNGO) stock soared 5.16% in the pre-market session on Monday, fueled by the company's preliminary financial results for Q4 2024 and full year 2024, which highlighted growth in its core optical genome mapping (OGM) business and significant cost reduction efforts.
While Bionano expects Q4 2024 revenue to decline around 25% year-over-year to $7.9-$8.1 million, primarily due to the discontinuation of some clinical service products, the company's installed base of OGM systems grew 14% to 371 units in 2024. Additionally, Q4 2024 revenue is projected to increase 30-33% compared to Q3 2024, showcasing recovery in the core business.
Importantly, Bionano's OGM technology continues to gain broader acceptance and recognition, with publications highlighting its utility, guidelines incorporating OGM nomenclature, and the establishment of a Category I CPT code for reimbursement. The company also made strides in reducing costs, with annualized operating expenses expected to decrease by approximately $100 million following restructuring efforts initiated in May 2023. Furthermore, Bionano raised additional capital to extend its cash runway.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。